SEARCH

SEARCH BY CITATION

References

  • ANDERSON, M.E. (1985). Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol., 113, 548555.
  • BALDWIN JR, A.S. (1996). The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol., 14, 649683.
  • BORS, W., HELLER, W., MICHEL, C. & SARAN, M. (1990). Flavonoids as antioxidants: determination of radical-scavenging efficiencies. Methods Enzymol., 186, 343355.
  • BRATTS, R. & LINDEN, M. (1996). Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment. Pharmacol. Ther., 10, 8190.
  • CANADA, A.T., GIANNELLA, E., NGUYEN, T.D. & MASON, R.P. (1990). The production of reactive oxygen species by dietary flavonols. Free Radic. Biol. Med., 9, 441449.
  • COOPER, H.S., MURTHY, S.N., SHAH, R.S. & SEDERGRAN, D.J. (1993). Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest., 69, 238249.
  • CRESPO, M.E., GALVEZ, J., CRUZ, T., OCETE, M.A. & ZARZUELO, A. (1999). Anti-inflammatory activity of diosmin and hesperidin in rat colitis induced by TNBS. Planta Med., 65, 651653.
  • CRUZ, T., GALVEZ, J., OCETE, M.A., CRESPO, M.E., SANCHEZ DE MEDINA, F. & ZARZUELO, A. (1998). Oral administration of rutoside can ameliorate inflammatory bowel disease in rats. Life Sci., 62, 687695.
  • ENNS, R. & SUTHERLAND, L. (1998). Adverse events of medical therapy for treatment for inflammatory bowel disease. In: Clinical Challenges in Inflammatory Bowel Disease. Diagnosis, Prognosis and Treatment, ed. Campieri, M., Bianchi-Porro, G., Fiocchi, C. & Schölmerich, J. pp. 113123. London: Kluwer Academic Publishers.
  • FIOCCHI, C. (1998). Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology, 115, 182205.
  • FUSS, I.J., MARTH, T., NEURATH, M.F., PEARLSTEIN, G.R., JAIN, A. & STROBER, W. (1999). Anti-interleukin 12 treatment regulates apoptosis of Th1T cells in experimental colitis in mice. Gastroenterology, 117, 10781088.
  • GALVEZ, J., COELHO, G., CRESPO, M.E., RODRIGUEZ-CABEZAS, M.E., CONCHA, A., GONZALEZ, M. & ZARZUELO, A. (2001). Intestinal anti-inflammatory activity of morin on chronic experimental colitis in the rat. Aliment. Pharmacol. Ther., 15, 20272039.
  • GALVEZ, J., CRUZ, T., CRESPO, E., OCETE, M.A., LORENTE, M.D., SANCHEZ DE MEDINA, F. & ZARZUELO, A. (1997). Rutoside as mucosal protective in acetic acid-induced rat colitis. Planta Med., 63, 409414.
  • GALVEZ, J., DE LA CRUZ, J.P., ZARZUELO, A., SANCHEZ DE MEDINA, F., JIMENEZ, J. & SANCHEZ DE LA CUESTA, F. (1994). Oral administration of quercitrin modifies intestinal oxidative status in rats. Gen. Pharmacol., 25, 12371243.
  • GAUDIO, E., TADDEI, G., VETUSCHI, A., SFERRA, R., FRIERI, G., RICCIARDI, G. & CAPRILLI, R. (1999). Dextran sulfate sodium (DSS) colitis in rats: clinical, structural, and ultrastructural aspects. Digest. Dis. Sci., 44, 14581475.
  • GRIFFITHS, M.J., MESSENT, M., MACALLISTER, R.J. & EVANS, T.W. (1993). Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br. J. Pharmacol., 110, 963968.
  • GRISHAM, M.B. (1994). Oxidants and free radicals in inflammatory bowel disease. Lancet, 344, 859861.
  • GRISHAM, M.B., PAVLICK, K.P., LAROUX, F.S., HOFFMAN, J., BHARWANI, S. & WOLF, R.E. (2002). Nitric oxide and chronic gut inflammation: controversies in inflammatory bowel disease. J. Investig. Med., 50, 272283.
  • HOGABOAM, C.M., JACOBSON, K., COLLINS, S.M. & BLENNERHASSETT, M.G. (1995). The selective beneficial effects of nitric oxide inhibition in experimental colitis. Am. J. Physiol., 268, G673G684.
  • KATZ, J.A., ITOH, J. & FIOCCHI, C. (1999). Pathogenesis of inflammatory bowel disease. Curr. Opin. Gastroenterol., 15, 291297.
  • KHO, Y.H., POOL, M.O., JANSMAN, F.G. & HARTING, J.W. (2001). Pharmacotherapeutic options in inflammatory bowel disease: an update. Pharm. World Sci., 23, 1721.
  • KIM, H.K., CHEON, B.S., KIM, Y.H., KIM, S.Y. & KIM, H.P. (1999). Effects of naturally occurring flavonoids on nitric oxide production in the macrophage cell line RAW 264.7 and their structure–activity relationships. Biochem. Pharmacol., 58, 759765.
  • KIM, H.P., MANI, I., IVERSEN, L. & ZIBOH, V.A. (1998). Effects of naturally-occurring flavonoids and biflavonoids on epidermal cyclooxygenase and lipoxygenase from guinea-pigs. Prostagland. Leukotr. Essent. Fatty Acids, 58, 1724.
  • KIMURA, H., MIURA, S., SHIGEMATSU, T., OHKUBO, N., TSUZUKI, Y., KUROSE, I., HIGUCHI, H., AKIBA, Y., HOKARI, R., HIROKAWA, M., SERIZAWA, H. & ISHII, H. (1997). Increased nitric oxide production and inducible nitric oxide synthase activity in colonic mucosa of patients with active ulcerative colitis and Crohn's disease. Digest. Dis. Sci., 42, 10471054.
  • KRAWISZ, J.E., SHARON, P. & STENSON, W.F. (1984). Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology, 87, 13441350.
  • KULLMANN, F., MESSMANN, H., ALT, M., GROSS, V., BOCKER, T., SCHOLMERICH, J. & RUSCHOFF, J. (2001). Clinical and histopathological features of dextran sulfate sodium induced acute and chronic colitis associated with dysplasia in rats. Int. J. Colorect. Dis., 16, 238246.
  • LOPEZ-LOPEZ, G., MORENO, L., COGOLLUDO, A., GALISTEO, M., IBARRA, M., DUARTE, J., LODI, F., TAMARGO, J. & PEREZ-VIZCAINO, F. (2004). Nitric oxide (NO) scavenging and NO protecting effects of quercetin and their biological significance in vascular smooth muscle. Mol. Pharmacol., 65, 851859.
  • MCKENZIE, S.J., BAKER, M.S., BUFFINTON, G.D. & DOE, W.F. (1996). Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J. Clin. Invest., 98, 136141.
  • MIDDLETON, E., KANDASWAMI, C. & THEOHARIDES, T.C. (2000). The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol. Rev., 52, 673751.
  • NEURATH, M.F., PETTERSSON, S., MEYER ZUM BUSCHENFELDE, K.H. & STROBER, W. (1996). Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat. Med., 2, 9981004.
  • OBERMEIER, F., KOJOUHAROFF, G., HANS, W., SCHOLMERICH, J., GROSS, V. & FALK, W. (1999). Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin. Exp. Immunol., 116, 238245.
  • PAVLICK, K.P., LAROUX, F.S., FUSELER, J., WOLF, R.E., GRAY, L., HOFFMAN, J. & GRISHAM, M.B. (2002). Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic. Biol. Med., 33, 311322.
  • PODOLSKY, D.K. & FIOCCHI, C. (2000). Cytokines, chemokines, growth factors, eicosanoids and other bioactive molecules in inflammatory bowel disease. In: Inflammatory Bowel Disease, ed. Kirsner, J.B. pp. 191207. Philadelphia: W.B. Saunders.
  • RACHMILEWITZ, D., KARMELI, F., OKON, E. & BURSZTYN, M. (1995). Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut, 37, 247255.
  • REUTER, B.K., ASFAHA, S., BURET, A., SHARKEY, K.A. & WALLACE, J.L. (1996). Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J. Clin. Investig., 98, 20762085.
  • RODRIGUEZ-CABEZAS, M.E., GALVEZ, J., LORENTE, M.D., CONCHA, A., CAMUESCO, D., AZZOUZ, S., OSUNA, A., REDONDO, L. & ZARZUELO, A. (2002). Dietary fiber down-regulates colonic tumor necrosis factor alpha and nitric oxide production in trinitrobenzenesulfonic acid-induced colitic rats. J. Nutr., 132, 32633271.
  • ROGLER, G., BRAND, K., VOGL, D., PAGE, S., HOFMEISTER, R., ANDUS, T., KNUECHEL, R., BAEUERLE, P.A., SCHOLMERICH, J. & GROSS, V. (1998). Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology, 115, 357369.
  • SALAS, A.M., GIRONELLA, M.M., SALAS, A.M., SORIANO, A., SANS, M., IOVANNA, J., PIQUE, J.M. & PANES, J. (2002). Nitric oxide supplementation ameliorates dextran sulfate sodium-induced colitis in mice. Lab. Invest., 82, 597607.
  • SANCHEZ DE MEDINA, F., GALVEZ, J., ROMERO, J.A. & ZARZUELO, A. (1996). Effect of quercitrin on acute and chronic experimental colitis in the rat. J. Pharmacol. Exp. Ther., 278, 771779.
  • SANCHEZ DE MEDINA, F., VERA, B., GALVEZ, J. & ZARZUELO, A. (2002). Effect of quercitrin on the early stages of hapten induced colonic inflammation in the rat. Life Sci., 70, 30973108.
  • SCHOTTELIUS, A.J.G. & BALDWIN JR, A.S. (1999). A role for transcription factor NF-κB in intestinal inflammation. Int. J. Colorect. Dis., 14, 1828.
  • SHARON, P. & STENSON, W.F. (1984). Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology, 86, 453460.
  • STEIN, R.B. & HANAUER, S.B. (2000). Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf., 23, 429448.
  • STUCCHI, A.F., SHOFER, S., LEEMAN, S., MATERNE, O., BEER, E., MCCLUNG, J., SHEBANI, K., MOORE, F., O'BRIEN, M. & BECKER, J.M. (2000). NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats. Am. J. Physiol., 279, G1298G1306.
  • TRAVIS, S.P.L. & JEWEL, D.P. (1994). Salicylates for ulcerative colitis – their mode of action. Pharmacol. Ther., 63, 135161.
  • TSAI, S.H., LIN-SHIAU, S.Y. & LIN, J.K. (1999). Suppression of nitric oxide synthase and the down-regulation of the activation of NF kappaB in macrophages by resveratrol. Br. J. Pharmacol., 126, 673680.
  • VELJACA, M., LESCH, C.A., PLLANA, R., SANCHEZ, B., CHAN, K. & GUGLIETTA, A. (1995). BPC-15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. J. Pharmacol. Exp. Ther., 272, 417422.
  • XIE, Q.W., KASHIWABARA, Y. & NATHAN, C. (1994). Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J. Biol. Chem., 269, 47054708.